10-Q: Forward Industries Reports Q1 2024 Results, Navigates Strategic Shift and Financial Challenges

Forward Industries reports a net loss for Q1 2024, impacted by the discontinuation of its retail segment and a decline in OEM distribution revenue, while also facing Nasdaq delisting concerns.

Summary

• Forward Industries reported a net loss of $354,000 for the quarter ended December 31, 2023, compared to a net loss of $430,000 in the same period last year.
• The company's loss from continuing operations was $381,000, a significant increase from the $91,000 loss in the prior year's quarter.
• Revenue decreased to $7.15 million from $9.75 million year-over-year, primarily due to a decline in the OEM distribution segment.
• The company discontinued its retail distribution segment in July 2023, which is now reported as discontinued operations.
• The OEM distribution segment saw a significant revenue decrease, particularly in diabetic product sales, while the design segment experienced a more modest decline.
• The company has a $1.3 million line of credit that matures on May 31, 2024, and a $850,000 promissory note due to Forward China on December 31, 2024.
• Forward China has agreed to limit the collection of outstanding payables to $500,000 in any 12-month period for payables outstanding as of October 30, 2023.
• The company is facing potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement and has requested a hearing with the Nasdaq Hearings Panel.

Sentiment

Score: 3

Explanation: The document presents a challenging financial picture with significant revenue declines, increased losses from continuing operations, and potential delisting from Nasdaq. While there are some positive aspects, such as improved gross margin and cost-cutting measures, the overall sentiment is negative due to the significant risks and uncertainties facing the company.

Positives

• The net loss improved compared to the same quarter last year, decreasing from $430,000 to $354,000.
• Gross margin increased to 23.0% from 20.2% due to a change in revenue mix and reduced sourcing fees.
• The company has taken steps to improve liquidity by limiting payables to Forward China and discontinuing the loss-making retail segment.
• The company has a $1.3 million line of credit available.
• The company has received shareholder approval for a reverse stock split.

Negatives

• The loss from continuing operations increased significantly to $381,000 from $91,000 year-over-year.
• Total revenue decreased by 26.7% to $7.15 million.
• The OEM distribution segment experienced a significant revenue decrease of 54.1%, particularly in diabetic product sales.
• The company is facing potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement.
• The company has a working capital deficit of $949,000 as of December 31, 2023.
• The company has a $850,000 promissory note due to Forward China on December 31, 2024.

Risks

• The company faces the risk of not regaining compliance with Nasdaq listing requirements, potentially leading to delisting.
• The company's reliance on a few large customers makes it vulnerable to fluctuations in demand.
• The loss of a major diabetic customer is expected to continue to negatively impact OEM distribution revenue.
• The company's financial performance is subject to the effects of COVID-19 and potential future outbreaks.
• The company's liquidity is dependent on the extension of the promissory note with Forward China and the availability of its line of credit.
• The company may not be able to raise additional capital on acceptable terms if needed.
• The company's business is subject to supply chain disruptions and issues at Chinese factories.

Future Outlook

The company expects improved performance in future periods due to the discontinuation of the retail segment. They also anticipate a continued decline in OEM distribution segment revenues due to the loss of a major diabetic customer. The company believes its existing cash balance and working capital will be sufficient to meet its liquidity needs through at least February 28, 2025. The company is considering its options regarding the reverse stock split and its Nasdaq listing.

Management Comments

• Management continues to monitor the various components of general and administrative expenses and how these costs are affected by inflationary and other factors.
• Management intends to adjust these costs as needed based on the overall needs of the business.
• Management believes that revenues from diabetic customers will decline in future periods.
• Management expects the loss of a major diabetic customer to continue to cause a significant decline in OEM distribution segment revenues in future periods.

Industry Context

The company's performance is impacted by broader trends in the medical and technology industries, including changes in demand for diabetic testing products and supply chain disruptions. The shift away from traditional carrying cases for diabetic products is a significant factor affecting the OEM distribution segment. The company is also facing challenges related to the global economy and the lingering effects of COVID-19.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards due to the unique combination of OEM distribution and design services offered by Forward Industries.
• However, the decline in OEM distribution revenue, particularly in diabetic products, is likely reflective of a broader trend in the medical device industry towards smaller, more portable devices that do not require carrying cases.
• The company's design segment performance can be compared to other product design and engineering firms, but specific benchmarks are not provided in the document.
• The company's gross margin of 23.0% is within the range of other companies in the manufacturing and distribution sector, but the specific comparison depends on the product mix and industry.

Related Party Transactions

• The company has a Buying Agency and Supply Agreement with Forward China, a related party.
• The company has a $850,000 promissory note payable to Forward China.
• The company has an agreement with Justwise Group Ltd., a company owned by the CEO, for design, marketing, and inventory management services related to Koble products.
• The company recorded revenue from a customer whose principal owner is an immediate family member of a shareholder and managing director of Forward China.
• The company recorded revenue from a customer who employs an immediate family member of a former member of our Audit, Governance and Compensation committees of our Board of Directors.

Stakeholder Impact

• Shareholders are negatively impacted by the company's financial losses and the potential delisting from Nasdaq.
• Employees may be affected by cost-cutting measures and potential restructuring.
• Customers may experience changes in product availability and pricing.
• Suppliers may be impacted by changes in the company's sourcing and purchasing practices.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to focus on expanding and diversifying its customer base in the OEM distribution segment.
• The company will continue to monitor and adjust general and administrative expenses.
• The company will determine whether to proceed with the reverse stock split.
• The company will attend a hearing with the Nasdaq Hearings Panel on April 9, 2024.
• The company will seek to extend the maturity date of the promissory note with Forward China.
• The company will seek to extend the line of credit beyond May 31, 2024.

Key Dates

Keywords

OEM distribution, design segment, discontinued operations, Nasdaq delisting, financial results, revenue decline, liquidity, Forward China, promissory note, reverse stock split